The American Journal of Medicine
Volume 123, Issue 3, Supplement , Pages S12-S18 , March 2010

Current Antihyperglycemic Treatment Guidelines and Algorithms for Patients with Type 2 Diabetes Mellitus

  • Lawrence Blonde, MD, FACP, FACE

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Lawrence Blonde, MD, FACP, FACE, Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Diabetes and Metabolism, Ochsner Medical Center, 1514 Jefferson Highway, New Orleans, Louisiana 70121

References 

  1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 2008;
  2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–79
  3. American Diabetes Association. Management. In:  Burant CF editors. Medical Management of Type 2 Diabetes. 6th ed.. Alexandria, VA: American Diabetes Association; 2008;p. 33–85
  4. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2008;52:65–73
  5. American Association of Clinical Endocrinologists Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1–68
  6. Texas Diabetes Council. Glycemic control algorithm for type 2 diabetes mellitus in children and adults. http://www.dshs.state.tx.us/diabetes/PDF/algorithms/Type%202%20Glycemic%20Control.pdfLast update: October 25, 2007. Accessed October 5, 2009
  7. Jellinger PS, Davidson JA, Blonde L, et al. ACE/ACCE Diabetes Road Map Task Force Road map to achieve glycemic control: naïve to therapy (type 2). http://www.medscape.com/viewarticle559463Accessed February 8, 2010
  8. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–559
  9. Canadian Diabetes Association. Canadian Diabetes Association 2008 clinical practice guidelines. Can J Diabetes. 2008;32(suppl 1):S1–S201
  10. American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care. 2010;33(suppl 1):S11–S61
  11. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203
  12. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in US adults?. Diabetes Care. 2008;31:81–86
  13. Funnell MM, Brown TL, Childs BP, et al. National standards for diabetes self-management education. Diabetes Care. 2010;33(suppl 1):S89–S96
  14. Joslin Diabetes Center. Joslin's library: managing your diabetes [Joslin Website]. http://www.joslin.org/managing_your_diabetes_707.aspAccessed October 5, 2009
  15. American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;32(suppl 1):S61–S77
  16. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32:187–192
  17. Gerstein HC, Miller ME, Byington RP, et al. ACCORD (Action to Control Cardiovascular Risk in Diabetes) Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559
  18. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572
  19. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139
  20. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DKfor the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med. 2007;147:417–422
  21. American College of Physicians Diabetes Initiative. https://www.acponline.org/atpro/timssnet/products/tnt_products.cfm?action=short&product_class=INITDER&PRODUCT_CLASS_DESCRIPTION=ACP%20Diabetes%20InitiativeLast update: 2008. Accessed October 5, 2009
  22. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194–206
  23. Stonehouse AH, Holcombe JH, Kendall DM. Management of type 2 diabetes: the role of incretin mimetics. Expert Opin Pharmacother. 2006;7:2095–2105
  24. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197
  25. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007;30:753–759
  26. Nathan DM, Balkau B, Bonora E, et al. International Expert Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–1334
  27. Santaguida PL, Balion C, Hunt D, et al. McMaster University Evidence-based Practice Center Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose (Evidence report/technology assessment No. 128 (prepared under Contract No. 290-02-0020). AHRQ Publication No. 05-E026-2). Rockville, MD: Agency for Healthcare Research and Quality; September 2005;http://www.ahrq.gov/Clinic/tp/impglutp.htm#ReportAccessed October 5, 2009
  28. Tuomilehto J, Lindström J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350
  29. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  30. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;15:2072–2077
  31. Gerstein HC, Yusuf S, Holman RR, et al. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;23:1096–1105
  32. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27:155–161
  33. ACTos NOW for the Prevention of Diabetes (ACT NOW) Study. Pioglitazone prevents conversion to diabetes among insulin-resistant patients. Presented at American Diabetes Association (ADA) 68th Scientific Sessions; June 11, 2008, San Francisco, CA. Available at: http://www.docguide.com/news/content.nsf/news/852571020057CCF685257465004F379A. Accessed February 5, 2010.
  34. International Diabetes Federation. The high risk approach. http://www.idf.org/home/index.cfm?unode=EE870A5F-7E95-425C-B927-77D395036DF6Last update: 2009. Accessed October 5, 2009
  35. Alexander GC, Sehgal NL, Moloney RM, et al. National trends in treatment of type 2 diabetes mellitus, 1994–2007. Arch Intern Med. 2008;168:2088–2094
  36. Sonnett TE, Levien TL, Neumiller JJ, et al. Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus. Clin Ther. 2009;31:245–259
  37. Scranton RE, Gaziano JM, Rutty D, et al. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either cycloset or placebo. BMC Endocr Disord. 2007;7:3
  38. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus [Banting Lecture]. Diabetes. 2009;58:773–795

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(09)01076-6

doi: 10.1016/j.amjmed.2009.12.005

The American Journal of Medicine
Volume 123, Issue 3, Supplement , Pages S12-S18 , March 2010

Article Tools

* Image Usage & Resolution